MAKING A NEW WAVE WITH
PREDICTIVE BIOMARKERS
We Hope to Make a World Free From Cancer by Developing
First-in-Class Anticancer Drugs Based on Predictive Biomarkers
We Strive to Make
the World Healthier
We develop first-in-class anticancer drugs based on predictive biomarkers for unmet medical needs.
By utilizing clinical information from one of the largest hospital in South Korea, we hope to make a world free from cancer.
Our dedicated researchers are making ceaseless efforts to develop new anticancer drugs.
We will continue to strive for the healthy life of mankind.
Corporate video
Our Scientific Approach
-
Patient Population
-
Biomarker Identification
-
Novel Anticancer Drug
Our researchers are developing predictive biomarkers that could identify patient's drug response to a certain therapy.
As a result, we can shorten the lead time, reduce the development cost and
increase the success rate in first-in-class anticancer drugs.
Press Relese
More-
Wellmarker Bio Announces Clinical Trial Collaboration with MSD to evaluate WM-A1-3...
Wellmarker Bio is pleased to sign a clinical collaboration and supply agreement with MSD (Merck & Co., Inc., Rahway, NJ, USA) to eval...
2023-02-08 -
Wellmarker Bio wins Good Company 'Bio' Award for the 4th Consecutive Year
September 2022 - Wellmarker Bio has been presented with the '8th Korean Good Company Awards' hosted by Money Today and sponsored by the Minist...
2022-09-15 -
WMBIO and Oncozen enters into licensing and collaboration agreement on “CMPD” TPD
&n...
2022-07-18